Get To Know Us

Juliana Woda, Ph.D.

Juliana Woda, Ph.D.

Scientific Co-founder

Juliana Woda, Ph.D. is an experienced biotechnology leader with expertise in translating biologics from preclinical to clinical programs; she is currently Senior Director, Innovations at Cleveland Clinic.  Previously, Dr. Woda worked for 12 years at multiple biotechnology companies, leading technologies through product development towards pharmaceutically acceptable therapeutics.  As Senior Director and Head of the Project Sourcing and Portfolio Opportunity Team at BioMotiv, Dr. Woda engaged with academic institutions, and funding partners to identify technologies and negotiate collaborations and license agreements.  Previously, as Director of Translational Research at Juventas, Dr. Woda led all aspects of translational research, including developing GMP manufacturing processes, leading to the successful submission of an IND and approval for a Phase II clinical study of a novel gene therapy product.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.